旅美学习,工作29年后, 谢恒博士于2017年回国担任深圳信立泰药业股份有限公司的首席医学官,负责公司创新药物的研发和临床策略。从2014至2017年初,谢博士曾任美国国家癌症研究院 (NCI), 癌症防治及临床研究部门资深医学官和药物研发总监,负责美国癌症防治研究网络中两大国家临床研究基地 SWOG and ECOG-ACRIN 的 I-III 期临床药物试验项目及数亿美元的国家科研经费的评选, 投放及监管。谢博士曾是这两大临床研究基地数据安全管理委员会 DSMB/DSMC 的委员,主持(chair)这些基地的临床药物试验(concepts/protocols) 的评审,批准 (‘Go/No-go’) 及实施, 通晓癌症药物研发的困难与障碍。从2001至2009, 谢博士曾任NCI,癌症治疗与评估部门 (CTEP) 的医学官及总监。从2009-2013,他在美国国立卫生研究院 (NIH), 国家转化医学中心 (NCATS), 临床医学部门 担任主管医学官并领导医师和博士组成的专业团队。在上述两个时期分别主管临床研究以及创新药物的 I-III 期的临床药物试验的研发经费与转化医学的数亿美元资金的投放和监管。谢博士多次参与了NIH和NCI的合作委员会,完成了十四项国家级的重大联合攻关项目的标书指南的撰写与发表, 项目的评审, 资助和成功结题,获得NIH/NCI的多次嘉奖及超常规的提拔并于2006升任至美国联邦政府的最高业务级别。谢博士在NIH/NCI期间一直享受美国联邦政府的特殊津贴,目前是中国国家癌症中心,美国梅奥癌症中心 (Mayo Clinic Cancer Center), 中国国家生物医学分析中心及中国健康促进基金会的国际顾问。   

赴美之前,谢博士是一名外科医师。分别于1998和1999年获得美国伯明翰大学细胞分子病理学的博士和约翰∙霍普金斯大学公共卫生学的硕士并于1998年通过美国的医师资格考试。他于 1999-2001 年在NCI完成了他的博士后研究,发表的文章函盖癌症细胞的信息传递,表皮生长因子受体引导的癌症入侵与转移及抗癌药物等。
 

现任深圳信立泰药业股份有限公司的首席医学官

前美国国家癌症研究院(NCI)资深医学官和创新药物研发总监

前美国国立卫生研究院(NIH)国家转化医学中心(NCATS)临床医学主管医学官

Dr. Heng Xie’s Bio

Heng Xie (M.D., Ph.D., and M.P.H.) is Chief Medical Officer at Salubris pharmaceutical Co., Ltd., China.  Prior to joining Salubris, Dr. Xie was a senior Medical Officer and Program Director at the National Cancer Institute (NCI). Dr. Xie oversaw two clinical trials groups including the Southwest Oncology Group (SWOG) and the ECOG-ACRIN Research Base, investigators’ initiated grants, and phase I to III cancer clinical trials. In addition, He was the Chair of the Cancer Prevention and Control Concept Protocol Review Committee for approving new clinical trial concepts and protocols and a standing member of both SWOG and ECOG-ACRIN’s Data Safety Monitoring Committee (DSMC).
Prior to joining the NCI, Dr. Xie worked as Medical Officer for the Cancer Therapy and Evaluation Program (CTEP) at the NCI and Supervisory Medical Officer for the Division of Clinical Innovation at the National Center for Advancing Translational Sciences (NCATS). He oversaw Surgical Oncology and Clinical Oncology programs that support Phase I-III cancer treatment trials where at the NCI and managed the Clinical Translational Science Awards (CTSA) program at the NCATS. Dr. Xie has published numerous funding initiatives, and received many NCI/NIH Merit Awards.
Dr. Xie was a surgeon in China before coming to the United States. He then obtained a Ph.D. in Molecular and Cellular Pathology from the University of Alabama at Birmingham and M.P.H. from the Johns Hopkins University. He also has the certification from Educational Commission for Foreign Medical Graduates (ECFMG). Dr. Xie obtained his postdoctoral training at the NCI, focused on Epidemiology, Biostatistics and Clinical Trials. His research and publications are in cell signal transduction, EGFR mediated mechanisms of tumor metastasis, and genetic molecular epidemiology.